المؤلفون: Holm H., Nagga K., Nilsson E. D., Ricci F., Melander O., Hansson O., Bachus E., Magnusson M., Fedorowski A.

المساهمون: Holm, H., Nagga, K., Nilsson, E. D., Ricci, F., Melander, O., Hansson, O., Bachus, E., Magnusson, M., Fedorowski, A.

مصطلحات موضوعية: adrenomedullin, atrial natriuretic peptide, biomarker, dementia, endothelial dysfunction, endothelin, Aged, Atrial Natriuretic Factor, Brain, Endothelin-1, Endothelium, Vascular, Female, Follow-Up Studie, Human, Male, Peptide Fragment, Prospective Studie, Protein Precursor, Risk Factors

الوصف: Background: Cerebral endothelial dysfunction occurs in a spectrum of neurodegenerative diseases. Whether biomarkers of microvascular endothelial dysfunction can predict dementia is largely unknown. We explored the longitudinal association of midregional pro-atrial natriuretic peptide (MR-proANP), C-terminal endothelin-1 (CT-proET-1) and midregional proadrenomedullin (MR-proADM) with dementia and subtypes amongst community-dwelling older adults. Methods: A population-based cohort of 5347 individuals (men, 70%; age, 69 ± 6 years) without prevalent dementia provided plasma for determination of MR-proANP, CT-proET-1 and MR-proADM. Three-hundred-and-seventy-three patients (7%) were diagnosed with dementia (120 Alzheimer's disease, 83 vascular, 102 mixed, and 68 other aetiology) over a period of 4.6 ± 1.3 years. Relations between baseline biomarker plasma concentrations and incident dementia were assessed using multivariable Cox regression analysis. Results: Higher levels of MR-proANP were significantly associated with increased risk of all-cause and vascular dementia (hazard ratio [HR] per 1 SD: 1.20, 95% confidence interval [CI], 1.07–1.36; P = 0.002, and 1.52; 1.21–1.89; P < 0.001, respectively). Risk of all-cause dementia increased across the quartiles of MR-proANP (p for linear trend = 0.004; Q4, 145–1681 pmol L−1 vs. Q1, 22–77 pmol L−1: HR: 1.83; 95%CI: 1.23–2.71) and was most pronounced for vascular type (p for linear trend = 0.005: HR: 2.71; 95%CI: 1.14–6.46). Moreover, the two highest quartiles of CT-proET-1 predicted vascular dementia with a cut-off value at 68 pmol L−1 (Q3–Q4, 68–432 pmol L−1 vs. Q1–Q2,4–68 pmol L−1; HR: 1.94; 95%CI: 1.12–3.36). Elevated levels of MR-proADM indicated no increased risk of developing dementia after adjustment for traditional risk factors. Conclusions: Elevated plasma concentration of MR-proANP is an independent predictor of all-cause and vascular dementia. Pronounced increase in CT-proET-1 indicates higher risk of vascular dementia.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28407377; info:eu-repo/semantics/altIdentifier/wos/WOS:000403441800008; volume:282; issue:1; firstpage:94; lastpage:101; numberofpages:8; journal:JOURNAL OF INTERNAL MEDICINE; http://hdl.handle.net/11564/719368Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85018419236

الإتاحة: https://doi.org/10.1111/joim.12621Test
http://hdl.handle.net/11564/719368Test

المؤلفون: Holm, H., Ricci, F., Di Martino, G., Bachus, E., Nilsson, E. D., Ballerini, P., Melander, O., Hansson, O., Nägga, Katarina, 1962, Magnusson, M., Fedorowski, A.

المصدر: Vascular pharmacology. 125

مصطلحات موضوعية: Dementia, Beta-blocker, Alzheimer, Vascular dementia, Mixed dementia

الوصف: There are a few studies that report cognitive impairment as a complication of treatment with beta-blockers. We aimed to evaluate the longitudinal association between use of beta-blockers, as a class, and incident risk of all-cause dementia, vascular dementia, Alzheimers and mixed dementia in the prospective population-based Malmo Preventive Project. We included 18,063 individuals (mean age 68.2, males 63.4%) followed up for 84,506 person-years. Dementia cases were retrieved from the Swedish National Patient Register and validated by review of medical records and neuroimaging data. We performed propensity score matching analysis, resulting in 3720 matched pairs of beta-blocker users and non-users at baseline, and multivariable Cox proportional-hazards regression. Overall, 122 study participants (1.6%) were diagnosed with dementia during the follow-up. Beta-blocker therapy was independently associated with increased risk of developing vascular dementia, regardless of confounding factors (HR: 1.72, 95%CI 1.01-3.78; p = .048). Conversely, treatment with beta-blockers was not associated with increased risk of all-cause, Alzheimers and mixed dementia (HR:1.15; 95%CI 0.80-1.66; p = .44; HR:0.85; 95%CI 0.48-1.54; P = .59 and HR:1.35; 95%CI 0.56-3.27; p = .50, respectively). We observed that use of beta-blockers, as a class, is associated with increased longitudinal risk of vascular dementia in the general elderly population, regardless of cardiovascular risk factors, prevalent or incident history of atrial fibrillation, stroke, coronary events and heart failure. Further studies are needed to confirm our findings in the general population and to explore the mechanisms underlying the relationship between use of beta-blockers and increased risk of vascular dementia.

وصف الملف: print

الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-164383Test

المؤلفون: Holm H., Nagga K., Nilsson E. D., Ricci F., Cinosi E., Melander O., Hansson O., Bachus E., Magnusson M., Fedorowski A.

المساهمون: Holm, H., Nagga, K., Nilsson, E. D., Ricci, F., Cinosi, E., Melander, O., Hansson, O., Bachus, E., Magnusson, M., Fedorowski, A.

مصطلحات موضوعية: Alzheimer disease, Dementia, Mixed dementia, Somatostatin, Vascular dementia, Aged, Biomarker, Vascular, Female, Human, Incidence, Male, Middle Aged, Peptide Fragment, Prognosi, Prospective Studie, Protein Precursor, Risk Factor, Sweden, Up-Regulation

الوصف: Background: Increased somatostatin plasma concentration has been found in patients with vascular dementia. However, it is unknown whether or not somatostatin levels may predict dementia development in the general population. To this end, we sought to assess the association of circulating N-terminal prosomatostatin (NT-proSST) with incident dementia among community-dwelling older adults. Methods: In the prospective population-based Malmö Preventive Project, 5,347 study participants (mean age: 69 ± 6years; 70% men) provided plasma for the determination of NT-proSST concentration. Of these, 373 participants (7%) were diagnosed with dementia (120 Alzheimer's disease, 83 vascular, 102 mixed, and 68 other aetiology) during a follow-up period of 4.6 ± 1.3 years. The association of NT-proSST with the risk of dementia and its subtypes was studied using multivariable-adjusted Cox regression models controlling for age, gender, body mass index, systolic blood pressure, antihypertensive treatment, smoking, diabetes, lipid levels and prevalent stroke. Results: Higher levels of NT-proSST were significantly associated with an increased risk of vascular dementia (hazard ratio [HR] per 1 SD: 1.29; 95% CI 1.05-1.59; p = 0.016), whereas no association was observed with Alzheimer's disease (HR per 1 SD: 0.99; 95% CI 0.81-1.20; p = 0.91), all-cause dementia (HR per 1 SD: 1.04; 95% CI 0.94-1.16; p = 0.44), and mixed dementia (HR per 1 SD: 0.98; 95% CI 0.79-1.21; p = 0.84). Levels of NT-proSST above 563 pmol/L (highest quartile) conferred distinctly increased risk of vascular dementia (HR 1.66; 95% CI 1.05-2.63; p = 0.029) compared with lower values. Conclusions: Higher levels of circulating N-terminal-prosomatostatin are associated with increased incidence of vascular dementia. Our findings might be of importance for the understanding of dementia development in older adults.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28854435; info:eu-repo/semantics/altIdentifier/wos/WOS:000417569500003; volume:44; issue:5-6; firstpage:259; lastpage:265; numberofpages:7; journal:CEREBROVASCULAR DISEASES; http://hdl.handle.net/11564/719865Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85028759284

الإتاحة: https://doi.org/10.1159/000479940Test
http://hdl.handle.net/11564/719865Test

المؤلفون: Holm, H., Nägga, K., Nilsson, E. D., Ricci, F., Melander, O., Hansson, O., Bachus, E., Fedorowski, A., Magnusson, M.

المصدر: Scientific Reports; 5/15/2020, Vol. 10 Issue 1, p1-8, 8p

مصطلحات موضوعية: ENKEPHALINS, VASCULAR dementia, BIOMARKERS, DEMENTIA, OPIOID peptides

مستخلص: Midregional Pro-enkephalin A (MR-PENK A) and N-terminal Protachykinin A (NT-PTA) have been associated with vascular dementia. However, the longitudinal relationship between these biomarkers and incident dementia has not been fully investigated. In the population-based Malmö Preventive Project, circulating levels of MR-PENK A and NT-PTA were determined in a random sample of 5,323 study participants (mean age: 69 ± 6 years) who were followed-up over a period of 4.6 ± 1.6 years. The study sample included 369 patients (7%) who were diagnosed in the same period with dementia. We analyzed relationship of MR-PENK A and NT-PTA with the risk of developing dementia by using multivariable-adjusted Cox regression models adjusted for traditional risk factors. Increased plasma levels of MR-PENK A were associated with higher risk of incident vascular dementia whereas no associations were found with all-cause or Alzheimer dementia. The risk of vascular dementia was mainly conferred by the highest quartile of MR-PENK as compared with lower quartiles. Elevated levels of NT-PTA yielded significant association with all-cause dementia or dementia subtypes. Elevated plasma concentration of MR-PENK A independently predicts vascular dementia in the general population. MR-PENK A may be used as an additional tool for identifying vascular subtype in ambiguous dementia cases. [ABSTRACT FROM AUTHOR]

: Copyright of Scientific Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Holm, H., Nägga, K., Nilsson, E. D., Ricci, F., Melander, O., Hansson, O., Bachus, E., Magnusson, M., Fedorowski, A., Nägga, K

المصدر: Journal of Internal Medicine; Jul2017, Vol. 282 Issue 1, p94-101, 8p, 3 Charts, 3 Graphs

مصطلحات موضوعية: ENDOTHELIUM diseases, BIOLOGICAL tags, DEMENTIA, ATRIAL natriuretic peptides, ADRENOMEDULLIN, DIAGNOSIS of dementia, BRAIN, ENDOTHELINS, ENDOTHELIUM, LONGITUDINAL method, PEPTIDE hormones, PEPTIDES, PROTEIN precursors

مستخلص: Background: Cerebral endothelial dysfunction occurs in a spectrum of neurodegenerative diseases. Whether biomarkers of microvascular endothelial dysfunction can predict dementia is largely unknown. We explored the longitudinal association of midregional pro-atrial natriuretic peptide (MR-proANP), C-terminal endothelin-1 (CT-proET-1) and midregional proadrenomedullin (MR-proADM) with dementia and subtypes amongst community-dwelling older adults.Methods: A population-based cohort of 5347 individuals (men, 70%; age, 69 ± 6 years) without prevalent dementia provided plasma for determination of MR-proANP, CT-proET-1 and MR-proADM. Three-hundred-and-seventy-three patients (7%) were diagnosed with dementia (120 Alzheimer's disease, 83 vascular, 102 mixed, and 68 other aetiology) over a period of 4.6 ± 1.3 years. Relations between baseline biomarker plasma concentrations and incident dementia were assessed using multivariable Cox regression analysis.Results: Higher levels of MR-proANP were significantly associated with increased risk of all-cause and vascular dementia (hazard ratio [HR] per 1 SD: 1.20, 95% confidence interval [CI], 1.07-1.36; P = 0.002, and 1.52; 1.21-1.89; P < 0.001, respectively). Risk of all-cause dementia increased across the quartiles of MR-proANP (p for linear trend = 0.004; Q4, 145-1681 pmol L-1 vs. Q1, 22-77 pmol L-1 : HR: 1.83; 95%CI: 1.23-2.71) and was most pronounced for vascular type (p for linear trend = 0.005: HR: 2.71; 95%CI: 1.14-6.46). Moreover, the two highest quartiles of CT-proET-1 predicted vascular dementia with a cut-off value at 68 pmol L-1 (Q3-Q4, 68-432 pmol L-1 vs. Q1-Q2,4-68 pmol L-1 ; HR: 1.94; 95%CI: 1.12-3.36). Elevated levels of MR-proADM indicated no increased risk of developing dementia after adjustment for traditional risk factors.Conclusions: Elevated plasma concentration of MR-proANP is an independent predictor of all-cause and vascular dementia. Pronounced increase in CT-proET-1 indicates higher risk of vascular dementia. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Internal Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)